{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:38Z","timestamp":1794047498165,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11102-026-01673-x","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:21:28Z","timestamp":1776259288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-2728","authenticated-orcid":false,"given":"Kevin C. J.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greisa","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Bernabeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Buchfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Freda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Henocque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria La","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Strasburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Neggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"1673_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27:7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"key":"1673_CR2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed S et al (2022) Clinical biology of the pituitary adenoma. Endocr Rev 43:1003\u20131037. https:\/\/doi.org\/10.1210\/endrev\/bnac010","journal-title":"Endocr Rev"},{"key":"1673_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667\u2013674. https:\/\/doi.org\/10.1210\/jc.2003-031199","journal-title":"J Clin Endocrinol Metab"},{"key":"1673_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21:667\u2013678. https:\/\/doi.org\/10.1210\/jc.2003-031199","journal-title":"Rev Endocr Metab Disord"},{"key":"1673_CR5","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/s0140-6736(01)06844-1","volume":"358","author":"AJ van der Lely","year":"2001","unstructured":"van der Lely, A. J. et al. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754\u20131759. https:\/\/doi.org\/10.1016\/s0140-6736(01)06844-1","journal-title":"Lancet"},{"key":"1673_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/EJE-18-0616","volume":"179","author":"M Buchfelder","year":"2018","unstructured":"Buchfelder M et al (2018) Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol 179:419\u2013427. https:\/\/doi.org\/10.1530\/EJE-18-0616","journal-title":"Eur J Endocrinol"},{"key":"1673_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/EJE-09-0322","volume":"161","author":"PJ Trainer","year":"2009","unstructured":"Trainer PJ (2009) ACROSTUDY: the first 5 years. Eur J Endocrinol 161:19\u201324. https:\/\/doi.org\/10.1530\/EJE-09-0322","journal-title":"Eur J Endocrinol"},{"key":"1673_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11102-015-0691-0","volume":"19","author":"I Bernabeu","year":"2016","unstructured":"Bernabeu I et al (2016) Safety of long-term treatment with pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary 19:127\u2013137. https:\/\/doi.org\/10.1007\/s11102-015-0691-0","journal-title":"Pituitary"},{"key":"1673_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ando.2015.10.003","volume":"76","author":"P Chanson","year":"2015","unstructured":"Chanson P et al (2015) Pegvisomant treatment in patients with acromegaly in clinical practice: the French ACROSTUDY. Ann Endocrinol (Paris) 76:664\u2013670. https:\/\/doi.org\/10.1016\/j.ando.2015.10.003","journal-title":"Ann Endocrinol (Paris)"},{"key":"1673_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12020-014-0393-9","volume":"48","author":"S Grottoli","year":"2015","unstructured":"Grottoli S et al (2015) ACROSTUDY: the Italian experience. Endocrine 48:334\u2013341. https:\/\/doi.org\/10.1007\/s12020-014-0393-9","journal-title":"Endocrine"},{"key":"1673_CR11","doi-asserted-by":"crossref","unstructured":"Araujo-Castro M et al (2024) Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocr Relat Cancer 31. 10.1530\/ERC-24-0043.","DOI":"10.1530\/ERC-24-0043"},{"key":"1673_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40618-022-01980-7","volume":"46","author":"R Pirchio","year":"2023","unstructured":"Pirchio R et al (2023) Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience. J Endocrinol Invest 46:1027\u20131038. https:\/\/doi.org\/10.1007\/s40618-022-01980-7","journal-title":"J Endocrinol Invest"},{"key":"1673_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","volume":"185","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M et al (2021) More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol 185:525\u2013538. https:\/\/doi.org\/10.1530\/EJE-21-0239","journal-title":"Eur J Endocrinol"},{"key":"1673_CR14","unstructured":"Cozzolino A et al (2018) Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. Mar 23 online ahead of print. <https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29590371>."},{"key":"1673_CR15","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"Feola T et al (2019) Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 104:2892\u20132902. https:\/\/doi.org\/10.1210\/jc.2018-02281","journal-title":"J Clin Endocrinol Metab"},{"key":"1673_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/EJE-16-0697","volume":"176","author":"NA Tritos","year":"2017","unstructured":"Tritos NA et al (2017) Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. Eur J Endocrinol 176:213\u2013220. https:\/\/doi.org\/10.1530\/EJE-16-0697","journal-title":"Eur J Endocrinol"},{"key":"1673_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4158\/EP14330.OR","volume":"21","author":"PU Freda","year":"2015","unstructured":"Freda PU et al (2015) Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract 21:264\u2013274. https:\/\/doi.org\/10.4158\/EP14330.OR","journal-title":"Endocr Pract"},{"key":"1673_CR18","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1530\/EJE-09-0333","volume":"161","author":"T Brue","year":"2009","unstructured":"Brue T et al (2009) Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur J Endocrinol 161:S11\u2013S17. https:\/\/doi.org\/10.1530\/EJE-09-0333","journal-title":"Eur J Endocrinol"},{"key":"1673_CR19","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1210\/jc.2011-2508","volume":"97","author":"AJ van der Lely","year":"2012","unstructured":"van der Lely AJ et al (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97:1589\u20131597. https:\/\/doi.org\/10.1210\/jc.2011-2508","journal-title":"J Clin Endocrinol Metab"},{"key":"1673_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/EJE-08-0910","volume":"161","author":"M Buchfelder","year":"2009","unstructured":"Buchfelder M et al (2009) Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161:27\u201335. https:\/\/doi.org\/10.1530\/EJE-08-0910","journal-title":"Eur J Endocrinol"},{"key":"1673_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgab726","volume":"107","author":"MR Gadelha","year":"2022","unstructured":"Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 107:297\u2013308. https:\/\/doi.org\/10.1210\/clinem\/dgab726","journal-title":"J Clin Endocrinol Metab"},{"key":"1673_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12020-018-1729-7","volume":"63","author":"LP Leonart","year":"2019","unstructured":"Leonart LP, Tonin FS, Ferreira VL, Fernandez-Llimos F, Pontarolo R (2019) Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine 63:18\u201326. https:\/\/doi.org\/10.1007\/s12020-018-1729-7","journal-title":"Endocrine"},{"key":"1673_CR23","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ et al (2014) Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99:1282\u20131290. https:\/\/doi.org\/10.1210\/jc.2013-3318","journal-title":"J Clin Endocrinol Metab"},{"key":"1673_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"1673_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/eje.1.02112","volume":"154","author":"A Colao","year":"2006","unstructured":"Colao A et al (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467\u2013477. https:\/\/doi.org\/10.1530\/eje.1.02112","journal-title":"Eur J Endocrinol"},{"key":"1673_CR26","doi-asserted-by":"publisher","first-page":"102884","DOI":"10.1016\/j.arcmed.2023.102884","volume":"54","author":"L Haberbosch","year":"2023","unstructured":"Haberbosch L, Strasburger CJ (2023) Efficacy and safety of pegvisomant in the treatment of acromegaly. Arch Med Res 54:102884. https:\/\/doi.org\/10.1016\/j.arcmed.2023.102884","journal-title":"Arch Med Res"},{"key":"1673_CR27","doi-asserted-by":"publisher","unstructured":"Huang W, Molitch ME (2018) Management of nonfunctioning pituitary adenomas (NFAs): observation. Pituitary 21, 162\u2013167. https:\/\/doi.org\/10.1007\/s11102-017-0856-0","DOI":"10.1007\/s11102-017-0856-0"},{"key":"1673_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","volume":"40","author":"A Giustina","year":"2017","unstructured":"Giustina A et al (2017) Pegvisomant in acromegaly: an update. J Endocrinol Invest 40:577\u2013589. https:\/\/doi.org\/10.1007\/s40618-017-0614-1","journal-title":"J Endocrinol Invest"},{"key":"1673_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1530\/EJE-08-0705","volume":"160","author":"M Marazuela","year":"2009","unstructured":"Marazuela M et al (2009) Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 160:535\u2013542. https:\/\/doi.org\/10.1530\/EJE-08-0705","journal-title":"Eur J Endocrinol"},{"key":"1673_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cen.12993","volume":"84","author":"AM Ramos-Levi","year":"2016","unstructured":"Ramos-Levi AM et al (2016) Long-term treatment with pegvisomant for acromegaly: a 10-year experience. Clin Endocrinol 84:540\u2013550. https:\/\/doi.org\/10.1111\/cen.12993","journal-title":"Clin Endocrinol"},{"key":"1673_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11102-016-0753-y","volume":"20","author":"NA Tritos","year":"2017","unstructured":"Tritos NA, Biller BM (2017) Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Pituitary 20:129\u2013135. https:\/\/doi.org\/10.1007\/s11102-016-0753-y","journal-title":"Pituitary"},{"key":"1673_CR32","doi-asserted-by":"publisher","unstructured":"Clemmons DR, Bidlingmaier M (2024) IGF-I assay methods and biologic variability: evaluation of acromegaly treatment response. Eur J Endocrinol 191. https:\/\/doi.org\/10.1093\/ejendo\/lvae065","DOI":"10.1093\/ejendo\/lvae065"},{"key":"1673_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","volume":"63","author":"T Brue","year":"2019","unstructured":"Brue T et al (2019) Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine 63:563\u2013572. https:\/\/doi.org\/10.1007\/s12020-018-1792-0","journal-title":"Endocrine"},{"key":"1673_CR34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3389\/fendo.2019.00509","volume":"10","author":"G Vila","year":"2019","unstructured":"Vila G, Jorgensen JOL, Luger A, Stalla GK (2019) Insulin resistance in patients with acromegaly. Front Endocrinol (Lausanne) 10:509. https:\/\/doi.org\/10.3389\/fendo.2019.00509","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01673-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01673-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01673-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:49:10Z","timestamp":1782409750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01673-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01673-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained for all participating centers, and all patients provided written informed consent before enrollment into the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Kevin C. J. Yuen is the principal investigator with research support to the Barrow Neurological Institute from Ascendis, Corcept, Chiesi, and Sparrow, has served as an occasional advisory board member for Novo Nordisk, Ascendis, Chiesi, Recordati, Crinetics, Xeris, and Neurocrine, and has served as an occasional speaker for Recordati, Neurocrine and Novo Nordisk. Greisa Vila has served as a clinical trial investigator (research support to Medical University of Vienna) for Takeda, Pfizer, Ipsen, Recordati, and Corcept, and has received occasional scientific con-sultant and\/or speaker fees from Pfizer, Takeda, Ipsen, Merck, Novo Nordisk, Recordati, and Lundbeck. Ignacio Bernabeu has received research grants from Pfizer and consultancy or speaker honoraria from Ipsen, Recordati, and Novo Nordisk. Michael Buchfelder has received a research grant and speaker honoraria from Pfizer. Pamela Freda has been a research investiga-tor with and received research grants from Pfizer. Robin Henocque and Daria La Torre are Pfizer employees and stock owners. Pietro Maffei is a principal investigator with research support to Padua University for clinical research studies with Pfizer, Camurus, and Recordati, and serves as an occasional scientific consultant for Pfizer and Recordati. Christian J. Strasburger received occasional consultancy or speaker honoraria from Novo Nordisk, Pfizer, Recordati, Sandoz-Hexal, Crinetics, Amolyth, Debiopharm, and Consilient Health. Sebastian Neggers has received research grants from Pfizer, and is a scientific consultant for Recordati, Novo Nordisk, Crinetics, and Ipsen. Thierry Brue has served as a clinical trial investigator for Xeris, Crinetics, Debiopharm, and Recordati, as an advisory board member for Pfizer, Recordati, and Novo Nordisk, and has received speaker fees from Pfizer, Recordati, and Novo Nordisk, and research grants from Pfizer and AFM (Association Fran\u00e7aise contre les Myopathies).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}